THE FEMALEBIOHACKER.

Women’s health.
Evidence in context.

Explore the tools
Menu
Published 13 September 2026
Educational information · Independent medical review has not been completed. Review policy
On this page
  1. Bottom line
  2. Disclosure matrix
  3. Why no leaderboard appears
  4. Non-endorsement boundary
  5. Authoritative reference points
  6. What a reproducible seller audit would require
  7. Claim-linked evidence notes
Transparency framework · no seller rankings

Gray-Market Peptide Vendor Transparency Methodology

A reproducible way to record what a seller discloses—without certifying product safety, legality, sterility or suitability for human use.1

Bottom line

Transparent documentation can reduce uncertainty about a claim, but it cannot authenticate the vial a buyer receives or convert a research-market product into approved medicine.1 The publication does not publish a “safe vendor” list or link to sellers.1

Disclosure matrix

Dimension Evidence to preserve Report as unknown when… Never infer
Legal identity Named company, physical jurisdiction, contact and ownership record Only a storefront or mailbox is visible Regulatory authorization
Product identity Exact molecule, salt/form, lot, amount and label image Names or quantities conflict Authenticity or clinical suitability
Analytical document Lot-linked final report, method, date, laboratory identity and verification path The report cannot be tied to the offered lot Chain of custody, future-batch quality or clinical benefit
Sterility/endotoxin Separate named tests, methods, sample and dates Only HPLC purity is shown Sterility from purity
Claims discipline Archived marketing claims and research-use wording Claims change or lack a source Human-use authorization from a disclaimer
Corrections/conflicts Correction channel, commercial relationships and update history No accountable process exists Independence from silence

Why no leaderboard appears

A score would imply a calibrated relationship between disclosure and product risk that has not been validated.1 Named seller conclusions would also require current source archiving, legal review, a correction/right-to-reply process and—where product quality is discussed—independent acquisition and testing. None of those conditions is replaced by a polished website or a COA image.1

Non-endorsement boundary

This method is for regulatory and document literacy. It offers no purchasing path, dose, cycle, injection instruction or vendor recommendation for unapproved investigational drugs.1

Authoritative reference points

Verification requirement: Named profiles require current official records and seller statements. This neutral framework does not score companies.

Transparency controls

What a reproducible seller audit would require

  1. Freeze a dated source set. Archive the exact public pages, terms, regulatory records and document links reviewed.
  2. Separate disclosures from verification. Record what the seller says, what an independent source confirms and what remains unknown.
  3. Use a correction pathway. Log a seller response without allowing it to silently replace the original snapshot.
  4. Recheck material facts. Product status, warning letters, ownership, terms and laboratory documents can change.1
  5. Do not rank beyond the method. Missing validated relationships between disclosure and harm mean no numerical safety score or “best vendor.”1

This framework can support market transparency research.1 It cannot support a safe-seller badge, purchasing recommendation or conclusion about an untested batch.1

Claim-linked evidence notes

Read the linked sources in context: a source’s population, outcome and limitations determine where it applies. Its inclusion does not imply endorsement of this publication or prove an individual result.

  1. Advertising and Marketing | Federal Trade Commission. Checked 2026-08-25.